BNET Industries
Onyx Pharmaceuticals Inc. (ONXX) is in the Pharma Industry
Latest News and Analysis
Onyx's $320M Bet on BTG's Anticancer Compound
Eben Tessari submits: BTG has granted the worldwide commercialization and development rights of BGC 945, a novel anticancer compound, to Onyx ONXX in exchange for a potential $320M. BGC 945 is a novel compound that inhibits thymidylate synthase (TS), an enzyme involved in cell growth and division. However,...
ONYX Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Question-and-Answer SessionThank you. [Operator Instructions]. Our first question comes from Jim Birchenough from Barclays Capital. Please go ahead. James Birchenough - Barclays Capital Yes. Hi guys. Hey, so a couple of questions. One just talking about the guidance you just provided as I wanted the map you are really...
Zacks Analyst Blog Highlights: Schlumberger Ltd., Amylin Pharmaceuticals, Inc., Eli Lilly & Co., Onyx Pharmaceuticals, Inc. and Diageo Plc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Schlumberger Ltd. (NYSE: SLB), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly...
5 Potential Buyout Targets in Biotech - Barron's
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
41 Stocks Returning 10% or More Last Week
Trader Mark submits: This week's list of top performers has high exposure to retail and solar; areas we have been moving into the past few weeks with greater weightings.... but more into solar than retail for the fund. This list continues to show us that "beaten down" merchandise from the...
Onyx Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer Session Operator Thank you. We will now begin the question-and-answer session. Operator Instructions Our first question comes from Jim. Please state your full name and the company you are from. James Birchenough - Lehman Hi. It is Jim Birchenough with Lehman. Tony Coles Hi, Jim. How are you?...
Onyx Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator Instructions Your first question comes from Jim Birchenough from Lehman Brothers. Please go ahead. Jim Birchenough - Lehman Brothers Yes, hi guys. Just wondering if you can break out for us particularly in the US, the distribution between renal cell and liver cancer sales?...
Onyx Pharmaceuticals Inc., Q4 2007 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions The first question comes from Steven Harr from Morgan Stanley. Please go ahead. Steven Harr - Morgan Stanley Hi. A couple of questions. First-off, on the safety side in the squamous cell population from the failed trial: Can you give us an idea or...
Biotech Battle Focusing on Onyx Pharmaceuticals, Inc., Vion Pharmaceuticals, Inc, and PainCare Holdings, Inc.
Comments made in this release are those of Maybach Financial Group and any questions or comments should be directed to the contact information located at the bottom of this release. Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total...
Onyx Pharmaceuticals Q3 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Yes, thank you. We will now begin the question-and-answer session. Operator Instructions We have Steve Harr from Morgan Stanley. Please state your question. Steve Harr - Morgan Stanley I want to get just a little better sense for what's driving some of the growth that you're seeing...
STOCK ALERT Newsletter Reports Timely Alert on Onyx Pharmaceuticals, Inc.
M2 PRESSWIRE-27 February 2007-StockHeadquarters.com: STOCK ALERT Newsletter Reports Timely Alert on Onyx Pharmaceuticals, Inc.C1994-2007 M2 COMMUNICATIONS LTD RDATE:27022007 StockHeadquarters.com, the "30 Day Free Trial, Just To Prove It" newsletter known for making stock alerts to its subscribers just days or...
STOCK ALERT Newsletter Reports On Its Outstanding Alert in Onyx Pharmaceuticals, Inc.
M2 PRESSWIRE-14 February 2007-StockHeadquarters.com: STOCK ALERT Newsletter Reports On Its Outstanding Alert in Onyx Pharmaceuticals, Inc.C1994-2007 M2 COMMUNICATIONS LTD RDATE:14022007 www.StockHeadquarters.com, the newsletter known for getting its subscribers in high-flying stocks before big surges in the stock price does it...
ONYX Pharmaceuticals, Inc. Announces Initial Public Offering
RICHMOND, Calif.--BUSINESS WIRE--May 8, 1996--ONYX Pharmaceuticals, Inc. announced today the initial public offering of 2,500,000 shares of Common Stock at a price of $12.00 per share, with an over allotment of an additional 375,000 shares.ONYX will be listed on the Nasdaq National Market system under the symbol of ONXX.Montgomery Securities...
Additional Resources
Zacks Bull and Bear of the Day Highlights: tw telecom, AutoNation, TDS, Iron Mountain and Onyx Pharmaceuticals
CHICAGO -- Zacks Equity Research highlights tw telecom, Inc. (Nasdaq: TWTC) as the Bull of the Day and AutoNation, Inc. (Nasdaq: AN) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Telephone & Data Systems (NYSE: TDS), Iron Mountain, Inc. (NYSE: IRM) and Onyx Pharmaceuticals,...
BTG licenses novel anticancer compound to Onyx Pharmaceuticals
BTG to receive $13m upfront plus potential milestones of up to $307m and sales royalties LONDON -- BTG plc (LSE: BGC), the life sciences company, announces it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG's novel anticancer compound, BGC 945. Under...
Yahoo shares plunge on Microsoft's cold shoulder
Yahoo Inc. fell as much as 17 percent in Nasdaq trading after Microsoft Corp. said it has no interest in acquiring the Sunnyvale Internet company. Yahoo Chief Executive Officer Jerry Yang said this week the Internet company is willing to sell, fueling investor speculation that Microsoft...
Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results
Nexavar Net Sales increase 73% over Third Quarter 2007 EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today reported its financial results for the three and nine months ended September 30, 2008. Onyx reported net income of $12.2 million, or $0.21 per diluted share,...
Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
BGC 945 Builds Upon a Proven Class of Drugs With Greater Tumor Selectivity EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it has in-licensed a novel targeted oncology compound, BGC 945, from BTG International Limited based in the United Kingdom. Under...
Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will present at the 2008 Credit Suisse Health Care Conference on Wednesday, November 12, at 10:00 a.m. Mountain Time (9:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on...
New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
- Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study of Liver Diseases - WAYNE, N.J. and EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1992
- CEO: Dr. N. Anthony Coles M.D.
- Employees: 153
Onyx Pharmaceuticals is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. Co. develops oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth. Co.'s product, NexavarŽ (sorafenib) tablets, are being developed with its collaborator Bayer HealthCare Pharmaceuticals, Inc., and is approved by the U.S. FDA, for advanced kidney cancer and liver cancer. NexavarŽ is an orally available kinase and angiogenesis inhibitor and serves as anticancer treatments that target signaling pathways important to the proliferation of cancer cells.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Merck & Co., Inc. Guidance Call Transcript
on Dec 04, 2008about MRK
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
Onyx Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Paul Goddard Ph.D.
Lead Director
Mr. Magnus Lundberg
Dr. N. Anthony Coles M.D.
Dr. Antonio J. Grillo-Lopez M.D.
Dr. Wendell D. Wierenga Ph.D.
Ms. Corinne H. Lyle
Mr. Thomas G. Wiggans
Contact Information
2100 Powell Street
Emeryville, CA
510 597-6500